Monte Rosa Therapeutics, Inc.
- GLUE
- NASDAQ
- Biotechnology
- Small-Molecule Protein Degraders
- Precision Medicine
$11.36
Today +6.57%Quote Oct 20, 2026, 08:00 PM UTC
−7.34%over the last month
Max drawdown −22.7%From 1-month high −9.8%3 months −52.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
173
Founded
2019
Market value
$969.2M
Quote Oct 20
Floor
$11.26
0.9% below price
Resistance
$12.27
8.0% above price
Price vs analyst targets
10 analysts
Lowest target
$19.00Highest target
$28.00
$19.00Highest target
$28.00
- Price $11.36
- Average target $24.83
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 119% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about GLUEPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free